Liquid Biopsy Market Forecasts to 2032 – Global Analysis By Product Type (Assay Kits & Reagents, Instruments, Services, and Other Product Types), Biomarker Type, Sample Type, Technology, Application, End User and By Geography
Description
According to Stratistics MRC, the Global Liquid Biopsy Market is accounted for $13447.02 million in 2025 and is expected to reach $32628.51 million by 2032 growing at a CAGR of 13.5% during the forecast period. Liquid biopsy is a non-invasive diagnostic technique that detects cancer and other diseases by analyzing biomarkers such as circulating tumor DNA (ctDNA), RNA, or exosomes present in body fluids like blood or urine. It offers a real-time snapshot of disease progression, enabling early detection, monitoring of treatment response, and detection of recurrence. Liquid biopsy provides a safer, quicker alternative to traditional tissue biopsies, enhancing patient care and personalized treatment strategies.
According to the International Agency for Research on Cancer (IARC), over 20.7 million new cancer cases are expected in 2023.
Market Dynamics:
Driver:
Increased preference for personalized medicine
The growing shift toward personalized medicine is a major catalyst for the expansion of the liquid biopsy market. As oncology care becomes more tailored, clinicians increasingly rely on minimally invasive tools like liquid biopsy to guide treatment decisions. These tests enable real-time monitoring of tumor dynamics, helping physicians adjust therapies based on individual molecular profiles. The ability to detect actionable mutations through circulating biomarkers supports the use of targeted therapies, improving patient outcomes. This rising demand for precision diagnostics is accelerating the adoption of liquid biopsy across research and clinical settings.
Restraint:
Limited clinical validation
Many liquid biopsy tests, particularly those detecting early-stage cancers or rare mutations, lack comprehensive, large-scale clinical trials to confirm their sensitivity, specificity, and overall reliability. Without robust validation, healthcare providers may hesitate to trust these tests for critical decisions such as diagnosis, treatment planning, or monitoring. This uncertainty also impacts regulatory approvals and insurance reimbursements, further delaying market penetration. To gain broader acceptance, more longitudinal studies and peer-reviewed evidence are essential to establish clinical utility across diverse patient populations.
Opportunity:
Advancements in genomics and next-generation sequencing (NGS)
NGS technologies enable high-throughput, accurate, and cost-effective analysis of circulating tumor DNA (ctDNA), exosomes, and other biomarkers from blood samples. These innovations allow for the detection of genetic mutations, copy number variations, and epigenetic changes with unprecedented sensitivity and specificity. As NGS becomes more accessible and integrated into clinical workflows, it enhances the ability to diagnose cancer early, monitor disease progression, and guide personalized treatment. Continuous improvements in sequencing speed, data analytics, and bioinformatics are further accelerating the clinical adoption of liquid biopsy.
Threat:
Complexity in data interpretation
The increasing complexity of genomic data generated by liquid biopsy tests poses a significant challenge. Interpreting multi-gene panels and distinguishing clinically relevant mutations from benign variants requires advanced bioinformatics expertise. Inconsistent reporting standards and lack of consensus on variant classification can lead to confusion among clinicians. This complexity may delay treatment decisions or result in suboptimal therapy selection. Smaller labs and healthcare providers may lack the infrastructure to manage and analyze such data effectively. Without streamlined interpretation tools and standardized guidelines, the full potential of liquid biopsy may remain underutilized.
Covid-19 Impact:
The COVID-19 pandemic had a dual impact on the liquid biopsy market. Initially, diagnostic delays and reduced hospital visits led to a temporary decline in cancer screening and monitoring procedures. However, the need for non-invasive, remote-friendly testing solutions brought renewed attention to liquid biopsy. As healthcare systems adapted, liquid biopsy emerged as a safer alternative to tissue biopsies, especially for immunocompromised patients. Post-pandemic, the market witnessed accelerated adoption driven by increased awareness of early detection and real-time monitoring.
The instruments segment is expected to be the largest during the forecast period
The instruments segment is expected to account for the largest market share during the forecast period, due to the critical role of platforms such as NGS systems, digital PCR, and microfluidic devices in enabling accurate biomarker detection. These instruments form the backbone of liquid biopsy workflows, supporting both research and clinical applications. Continuous innovation in sequencing speed, throughput, and automation is enhancing test efficiency and scalability. As demand for high-sensitivity diagnostics grows, investment in advanced instrumentation is expected to rise.
The specialty clinics segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the specialty clinics segment is predicted to witness the highest growth rate. These clinics are increasingly adopting liquid biopsy for cancer screening, therapy selection, and recurrence monitoring. Their focused expertise and streamlined workflows make them ideal settings for implementing advanced diagnostics. As awareness of personalized medicine grows, patients are turning to specialty centers for tailored care. Additionally, partnerships between diagnostic companies and specialty clinics are expanding access to cutting-edge tests.
Region with largest share:
During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by rising cancer incidence, expanding healthcare infrastructure, and increasing government investment in precision medicine. Countries like China, India, and Japan are witnessing rapid adoption of advanced diagnostics, including liquid biopsy. Local players are also entering the market with cost-effective solutions tailored to regional needs. Public-private partnerships and favorable regulatory reforms are further accelerating market penetration.
Region with highest CAGR:
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to the region benefits from a well-established healthcare system, strong R&D ecosystem, and early adoption of genomic technologies. Regulatory approvals for liquid biopsy-based companion diagnostics are increasing, boosting clinical confidence. Additionally, rising demand for non-invasive cancer screening and monitoring is fueling test volumes. Strategic collaborations between biotech firms, academic institutions, and healthcare providers are driving innovation.
Key players in the market
Some of the key players in Liquid Biopsy Market include F. Hoffmann-La Roche Ltd., Menarini Silicon Biosystems, Guardant Health Inc., Freenome Holdings, Inc., Illumina Inc., Biocept, Inc., Thermo Fisher Scientific Inc., ANGLE plc, Exact Sciences Corporation, Caris Life Sciences, Natera Inc., NeoGenomics Laboratories, QIAGEN N.V., Lucence Health Inc., Bio-Rad Laboratories Inc., Foundation Medicine, Inc., Epigenomics AG, Johnson & Johnson Services Inc., Myriad Genetics, Inc., and Sysmex Corporation.
Key Developments:
In May 2025, Roche announced a strategic collaboration with Broad Clinical Labs to develop and pilot groundbreaking applications using Roche’s recently unveiled next-generation sequencing (NGS) Sequencing By Expansion (SBX) technology. This collaboration will focus on harnessing the power of the SBX technology to transform clinical genomics and biomedical discovery. It will also aim to establish the SBX technology as a routine offering for fast, scalable sequencing for Broad Clinical Lab’s research community.
In July 2022, Menarini Silicon Biosystems Inc, announced at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo that they have entered into a commercial agreement for the exclusive distribution of the CHORUS TRIO immunometric assay system in the United States of America.
Product Types Covered:
• Assay Kits & Reagents
• Instruments
• Services
• Other Product Types
Biomarker Types Covered:
• Circulating Tumor Cells (CTCs)
• Circulating Tumor DNA (ctDNA)
• Exosomes and Extracellular Vesicles
• Cell-Free DNA (cfDNA)
• Cell-Free RNA (cfRNA)
• Circulating Proteins
• Other Biomarker Types
Sample Types Covered:
• Blood
• Saliva
• Urine
• Fecal-Based Sampling
• Other Body Fluids
Technologies Covered:
• Next-Generation Sequencing (NGS)
• Beads, Emulsion, Amplification, and Magnetics (BEAMing)
• Polymerase Chain Reaction (PCR)
• Digital Droplet PCR (ddPCR)
• Other Technologies
Applications Covered:
• Cancer Applications
• Non-Cancer Applications
• Other Applications
End Users Covered:
• Hospitals and Physician Laboratories
• Diagnostic Laboratories
• Academic and Research Institutes
• Biopharmaceutical and Biotechnology Companies
• Reference Laboratories
• Specialty Clinics
• Other End Users
Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
According to the International Agency for Research on Cancer (IARC), over 20.7 million new cancer cases are expected in 2023.
Market Dynamics:
Driver:
Increased preference for personalized medicine
The growing shift toward personalized medicine is a major catalyst for the expansion of the liquid biopsy market. As oncology care becomes more tailored, clinicians increasingly rely on minimally invasive tools like liquid biopsy to guide treatment decisions. These tests enable real-time monitoring of tumor dynamics, helping physicians adjust therapies based on individual molecular profiles. The ability to detect actionable mutations through circulating biomarkers supports the use of targeted therapies, improving patient outcomes. This rising demand for precision diagnostics is accelerating the adoption of liquid biopsy across research and clinical settings.
Restraint:
Limited clinical validation
Many liquid biopsy tests, particularly those detecting early-stage cancers or rare mutations, lack comprehensive, large-scale clinical trials to confirm their sensitivity, specificity, and overall reliability. Without robust validation, healthcare providers may hesitate to trust these tests for critical decisions such as diagnosis, treatment planning, or monitoring. This uncertainty also impacts regulatory approvals and insurance reimbursements, further delaying market penetration. To gain broader acceptance, more longitudinal studies and peer-reviewed evidence are essential to establish clinical utility across diverse patient populations.
Opportunity:
Advancements in genomics and next-generation sequencing (NGS)
NGS technologies enable high-throughput, accurate, and cost-effective analysis of circulating tumor DNA (ctDNA), exosomes, and other biomarkers from blood samples. These innovations allow for the detection of genetic mutations, copy number variations, and epigenetic changes with unprecedented sensitivity and specificity. As NGS becomes more accessible and integrated into clinical workflows, it enhances the ability to diagnose cancer early, monitor disease progression, and guide personalized treatment. Continuous improvements in sequencing speed, data analytics, and bioinformatics are further accelerating the clinical adoption of liquid biopsy.
Threat:
Complexity in data interpretation
The increasing complexity of genomic data generated by liquid biopsy tests poses a significant challenge. Interpreting multi-gene panels and distinguishing clinically relevant mutations from benign variants requires advanced bioinformatics expertise. Inconsistent reporting standards and lack of consensus on variant classification can lead to confusion among clinicians. This complexity may delay treatment decisions or result in suboptimal therapy selection. Smaller labs and healthcare providers may lack the infrastructure to manage and analyze such data effectively. Without streamlined interpretation tools and standardized guidelines, the full potential of liquid biopsy may remain underutilized.
Covid-19 Impact:
The COVID-19 pandemic had a dual impact on the liquid biopsy market. Initially, diagnostic delays and reduced hospital visits led to a temporary decline in cancer screening and monitoring procedures. However, the need for non-invasive, remote-friendly testing solutions brought renewed attention to liquid biopsy. As healthcare systems adapted, liquid biopsy emerged as a safer alternative to tissue biopsies, especially for immunocompromised patients. Post-pandemic, the market witnessed accelerated adoption driven by increased awareness of early detection and real-time monitoring.
The instruments segment is expected to be the largest during the forecast period
The instruments segment is expected to account for the largest market share during the forecast period, due to the critical role of platforms such as NGS systems, digital PCR, and microfluidic devices in enabling accurate biomarker detection. These instruments form the backbone of liquid biopsy workflows, supporting both research and clinical applications. Continuous innovation in sequencing speed, throughput, and automation is enhancing test efficiency and scalability. As demand for high-sensitivity diagnostics grows, investment in advanced instrumentation is expected to rise.
The specialty clinics segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the specialty clinics segment is predicted to witness the highest growth rate. These clinics are increasingly adopting liquid biopsy for cancer screening, therapy selection, and recurrence monitoring. Their focused expertise and streamlined workflows make them ideal settings for implementing advanced diagnostics. As awareness of personalized medicine grows, patients are turning to specialty centers for tailored care. Additionally, partnerships between diagnostic companies and specialty clinics are expanding access to cutting-edge tests.
Region with largest share:
During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by rising cancer incidence, expanding healthcare infrastructure, and increasing government investment in precision medicine. Countries like China, India, and Japan are witnessing rapid adoption of advanced diagnostics, including liquid biopsy. Local players are also entering the market with cost-effective solutions tailored to regional needs. Public-private partnerships and favorable regulatory reforms are further accelerating market penetration.
Region with highest CAGR:
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to the region benefits from a well-established healthcare system, strong R&D ecosystem, and early adoption of genomic technologies. Regulatory approvals for liquid biopsy-based companion diagnostics are increasing, boosting clinical confidence. Additionally, rising demand for non-invasive cancer screening and monitoring is fueling test volumes. Strategic collaborations between biotech firms, academic institutions, and healthcare providers are driving innovation.
Key players in the market
Some of the key players in Liquid Biopsy Market include F. Hoffmann-La Roche Ltd., Menarini Silicon Biosystems, Guardant Health Inc., Freenome Holdings, Inc., Illumina Inc., Biocept, Inc., Thermo Fisher Scientific Inc., ANGLE plc, Exact Sciences Corporation, Caris Life Sciences, Natera Inc., NeoGenomics Laboratories, QIAGEN N.V., Lucence Health Inc., Bio-Rad Laboratories Inc., Foundation Medicine, Inc., Epigenomics AG, Johnson & Johnson Services Inc., Myriad Genetics, Inc., and Sysmex Corporation.
Key Developments:
In May 2025, Roche announced a strategic collaboration with Broad Clinical Labs to develop and pilot groundbreaking applications using Roche’s recently unveiled next-generation sequencing (NGS) Sequencing By Expansion (SBX) technology. This collaboration will focus on harnessing the power of the SBX technology to transform clinical genomics and biomedical discovery. It will also aim to establish the SBX technology as a routine offering for fast, scalable sequencing for Broad Clinical Lab’s research community.
In July 2022, Menarini Silicon Biosystems Inc, announced at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo that they have entered into a commercial agreement for the exclusive distribution of the CHORUS TRIO immunometric assay system in the United States of America.
Product Types Covered:
• Assay Kits & Reagents
• Instruments
• Services
• Other Product Types
Biomarker Types Covered:
• Circulating Tumor Cells (CTCs)
• Circulating Tumor DNA (ctDNA)
• Exosomes and Extracellular Vesicles
• Cell-Free DNA (cfDNA)
• Cell-Free RNA (cfRNA)
• Circulating Proteins
• Other Biomarker Types
Sample Types Covered:
• Blood
• Saliva
• Urine
• Fecal-Based Sampling
• Other Body Fluids
Technologies Covered:
• Next-Generation Sequencing (NGS)
• Beads, Emulsion, Amplification, and Magnetics (BEAMing)
• Polymerase Chain Reaction (PCR)
• Digital Droplet PCR (ddPCR)
• Other Technologies
Applications Covered:
• Cancer Applications
• Non-Cancer Applications
• Other Applications
End Users Covered:
• Hospitals and Physician Laboratories
• Diagnostic Laboratories
• Academic and Research Institutes
• Biopharmaceutical and Biotechnology Companies
• Reference Laboratories
• Specialty Clinics
• Other End Users
Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Table of Contents
200 Pages
- 1 Executive Summary
- 2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
- 3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Application Analysis
- 3.7 End User Analysis
- 3.8 Emerging Markets
- 3.9 Impact of Covid-19
- 4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
- 5 Global mRNA Therapeutics Market, By Type
- 5.1 Introduction
- 5.2 Prophylactic Vaccines
- 5.3 Therapeutic Vaccines
- 5.4 Monoclonal Antibodies
- 5.5 Gene Editing Therapies
- 5.6 Protein Replacement Therapies
- 5.7 Other Types
- 6 Global mRNA Therapeutics Market, By mRNA Type
- 6.1 Introduction
- 6.2 Conventional Non-amplifying
- 6.3 Self-amplifying
- 7 Global mRNA Therapeutics Market, By Delivery System
- 7.1 Introduction
- 7.2 Lipid Nanoparticles (LNPs)
- 7.3 Cationic Nanoemulsions
- 7.4 Polymer-Based Carriers
- 7.5 Peptide-Based Carriers
- 7.6 Other Delivery Systems
- 8 Global mRNA Therapeutics Market, By Route of Administration
- 8.1 Introduction
- 8.2 Intramuscular
- 8.3 Intravenous
- 8.4 Subcutaneous
- 8.5 Intradermal
- 9 Global mRNA Therapeutics Market, By Application
- 9.1 Introduction
- 9.2 Infectious Diseases
- 9.3 Cancer
- 9.4 Genetic Disorders
- 9.5 Cardiovascular Diseases
- 9.6 Autoimmune Diseases
- 9.7 Respiratory Diseases
- 9.8 Other Applications
- 10 Global mRNA Therapeutics Market, By End User
- 10.1 Introduction
- 10.2 Hospitals & Clinics
- 10.3 Contract Research Organizations (CROs)
- 10.4 Research Institutes
- 10.5 Biopharmaceutical Companies
- 10.6 Other End Users
- 11 Global mRNA Therapeutics Market, By Geography
- 11.1 Introduction
- 11.2 North America
- 11.2.1 US
- 11.2.2 Canada
- 11.2.3 Mexico
- 11.3 Europe
- 11.3.1 Germany
- 11.3.2 UK
- 11.3.3 Italy
- 11.3.4 France
- 11.3.5 Spain
- 11.3.6 Rest of Europe
- 11.4 Asia Pacific
- 11.4.1 Japan
- 11.4.2 China
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 New Zealand
- 11.4.6 South Korea
- 11.4.7 Rest of Asia Pacific
- 11.5 South America
- 11.5.1 Argentina
- 11.5.2 Brazil
- 11.5.3 Chile
- 11.5.4 Rest of South America
- 11.6 Middle East & Africa
- 11.6.1 Saudi Arabia
- 11.6.2 UAE
- 11.6.3 Qatar
- 11.6.4 South Africa
- 11.6.5 Rest of Middle East & Africa
- 12 Key Developments
- 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 12.2 Acquisitions & Mergers
- 12.3 New Product Launch
- 12.4 Expansions
- 12.5 Other Key Strategies
- 13 Company Profiling
- 13.1 ModernaTX, Inc.
- 13.2 Shape Therapeutics
- 13.3 BioNTech SE
- 13.4 Orbital Therapeutics
- 13.5 Pfizer Inc.
- 13.6 Beam Therapeutics Inc.
- 13.7 AstraZeneca plc
- 13.8 Sangamo Therapeutics
- 13.9 Sanofi
- 13.10 Ethris GmbH
- 13.11 GlaxoSmithKline plc (GSK)
- 13.12 Gennova Biopharmaceuticals Limited
- 13.13 CureVac N.V.
- 13.14 Daiichi Sankyo Company, Limited
- 13.15 Arcturus Therapeutics Holdings Inc.
- 13.16 Vertex Pharmaceuticals Incorporated
- List of Tables
- Table 1 Global mRNA Therapeutics Market Outlook, By Region (2024-2032) ($MN)
- Table 2 Global mRNA Therapeutics Market Outlook, By Type (2024-2032) ($MN)
- Table 3 Global mRNA Therapeutics Market Outlook, By Prophylactic Vaccines (2024-2032) ($MN)
- Table 4 Global mRNA Therapeutics Market Outlook, By Therapeutic Vaccines (2024-2032) ($MN)
- Table 5 Global mRNA Therapeutics Market Outlook, By Monoclonal Antibodies (2024-2032) ($MN)
- Table 6 Global mRNA Therapeutics Market Outlook, By Gene Editing Therapies (2024-2032) ($MN)
- Table 7 Global mRNA Therapeutics Market Outlook, By Protein Replacement Therapies (2024-2032) ($MN)
- Table 8 Global mRNA Therapeutics Market Outlook, By Other Types (2024-2032) ($MN)
- Table 9 Global mRNA Therapeutics Market Outlook, By mRNA Type (2024-2032) ($MN)
- Table 10 Global mRNA Therapeutics Market Outlook, By Conventional Non-amplifying (2024-2032) ($MN)
- Table 11 Global mRNA Therapeutics Market Outlook, By Self-amplifying (2024-2032) ($MN)
- Table 12 Global mRNA Therapeutics Market Outlook, By Delivery System (2024-2032) ($MN)
- Table 13 Global mRNA Therapeutics Market Outlook, By Lipid Nanoparticles (LNPs) (2024-2032) ($MN)
- Table 14 Global mRNA Therapeutics Market Outlook, By Cationic Nanoemulsions (2024-2032) ($MN)
- Table 15 Global mRNA Therapeutics Market Outlook, By Polymer-Based Carriers (2024-2032) ($MN)
- Table 16 Global mRNA Therapeutics Market Outlook, By Peptide-Based Carriers (2024-2032) ($MN)
- Table 17 Global mRNA Therapeutics Market Outlook, By Other Delivery Systems (2024-2032) ($MN)
- Table 18 Global mRNA Therapeutics Market Outlook, By Route of Administration (2024-2032) ($MN)
- Table 19 Global mRNA Therapeutics Market Outlook, By Intramuscular (2024-2032) ($MN)
- Table 20 Global mRNA Therapeutics Market Outlook, By Intravenous (2024-2032) ($MN)
- Table 21 Global mRNA Therapeutics Market Outlook, By Subcutaneous (2024-2032) ($MN)
- Table 22 Global mRNA Therapeutics Market Outlook, By Intradermal (2024-2032) ($MN)
- Table 23 Global mRNA Therapeutics Market Outlook, By Application (2024-2032) ($MN)
- Table 24 Global mRNA Therapeutics Market Outlook, By Infectious Diseases (2024-2032) ($MN)
- Table 25 Global mRNA Therapeutics Market Outlook, By Cancer (2024-2032) ($MN)
- Table 26 Global mRNA Therapeutics Market Outlook, By Genetic Disorders (2024-2032) ($MN)
- Table 27 Global mRNA Therapeutics Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN)
- Table 28 Global mRNA Therapeutics Market Outlook, By Autoimmune Diseases (2024-2032) ($MN)
- Table 29 Global mRNA Therapeutics Market Outlook, By Respiratory Diseases (2024-2032) ($MN)
- Table 30 Global mRNA Therapeutics Market Outlook, By Other Applications (2024-2032) ($MN)
- Table 31 Global mRNA Therapeutics Market Outlook, By End User (2024-2032) ($MN)
- Table 32 Global mRNA Therapeutics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
- Table 33 Global mRNA Therapeutics Market Outlook, By Contract Research Organizations (CROs) (2024-2032) ($MN)
- Table 34 Global mRNA Therapeutics Market Outlook, By Research Institutes (2024-2032) ($MN)
- Table 35 Global mRNA Therapeutics Market Outlook, By Biopharmaceutical Companies (2024-2032) ($MN)
- Table 36 Global mRNA Therapeutics Market Outlook, By Other End Users (2024-2032) ($MN)
- Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
